Sigyn Therapeutics, Inc. (SIGY)

USD 3.15

(0.0%)

Market Cap (In USD)

5.05 Million

Revenue (In USD)

-

Net Income (In USD)

-4.14 Million

Avg. Volume

226.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.15-7.96
PE
-
EPS
-
Beta Value
-1.027
ISIN
US82674U1060
CUSIP
82674U106
CIK
1642159
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. James A. Joyce Ph.D.
Employee Count
-
Website
https://www.sigyntherapeutics.com
Ipo Date
2021-01-08
Details
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.